MDGL Price Prediction Next Week
Analysis and Insights
Technical Analysis:
MDGL's stock is currently trading at $327.98 as of 2025-03-10. The technical indicators suggest a neutral to slightly bearish sentiment:
- RSI (14-period): 50.17, indicating a neutral position.
- MACD: The MACD line is above the signal line (1.60 vs. -1.39), suggesting bullish momentum, but the MACD histogram is negative, indicating weakening upward momentum.
- Fibonacci Levels: The stock is approaching the lower end of the Fibonacci range, with a pivot point at $335.90, resistance at $365.66, and support at $306.14.
News Impact:
- Insider Selling: Significant insider selling activity, with Senior VP Robert E. Waltermire selling 1,777 shares recently, representing 10.5% of his holdings. This could indicate a lack of confidence among insiders.
- Institutional Sentiment: Mixed sentiment among institutional investors, with equal numbers adding and reducing their positions in the most recent quarter.
- Analyst Ratings: A Strong Buy consensus with a price target of $413.14, suggesting a 24.4% upside from current levels.
Conclusion:
Based on the technical indicators and news sentiment, MDGL is expected to trade in a range of $306.14 to $365.66 next week. The stock is currently near the lower end of this range, and while the bullish MACD signal suggests some upward potential, the insider selling activity and mixed institutional sentiment may limit significant gains.
Recommendation: Buy at the lower end of the range ($306.14) with a target price of $365.66.
MDGL Similar Chart Price Prediction
The price of MDGL is predicted to go up -6.92%, based on the high correlation periods with COE. The similarity of these two price pattern on the periods is 93.24%.
MDGL
COE
Down: -6.92%Similarity: 93.24%
MDGL Revenue Forecast
MDGL EPS Forecast
MDGL FAQs
What is MDGL revenue forecast for next quarter？
What is MDGL eps forecast for next quarter？
MDGL Analyst's Forecast
Mayank Mamtani
B. Riley Securities
Hold
2024-11-05
Price Target
$194 → $236
Downside
-30.1%
B. Riley analyst Mayank Mamtani raised the firm's price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal's Q3 earnings "blowout" print reaffirmed Rezdiffra's robust early launch trends in advanced nonalcoholic steatohepatitis patients and competitor Novo Nordisk's (NVO) positive Phase III ESSENCE liver biopsy readout a net positive at large for the MASH therapeutics' landscape and drove a 40% equity move, the analyst tells investors in a research note. Further upside for Madrigal is limited, however, due to flattening Rezdiffra new prescriptions and the floodgates opened for multiple next-gen GLP1 based therapies, the firm says.
Eliana Merle
UBS
Strong Buy
2024-11-01
Price Target
$411 → $441
Upside
+37.99%
Jay Olson
Oppenheimer
Buy
2024-10-23
Price Target
$375 → $350
Upside
+72.86%
